Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
Authors
Keywords
-
Journal
DRUG SAFETY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-01-16
DOI
10.1007/s40264-018-0773-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Restoration of mutant hERG stability by inhibition of HDAC6
- (2018) Peili Li et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways
- (2018) Manon Lernoux et al. PHARMACOLOGICAL RESEARCH
- Givinostat reduces adverse cardiac remodeling through regulating fibroblasts activation
- (2018) Marika Milan et al. Cell Death & Disease
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
- (2018) Amila Suraweera et al. Frontiers in Oncology
- Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead
- (2018) Rashmi R. Shah et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study
- (2017) Vincent Ribrag et al. HAEMATOLOGICA
- Histone Deacetylase Inhibitors as Anticancer Drugs
- (2017) Tomas Eckschlager et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Psychotropic drugs and ventricular repolarisation: The effects on QT interval, T-peak to T-end interval and QT dispersion
- (2017) Tiziano Acciavatti et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Targeting Class I Histone Deacetylases in a “Complex” Environment
- (2017) Christopher J. Millard et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study
- (2017) Vincent Ribrag et al. HAEMATOLOGICA
- Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia
- (2016) Elena Ceccacci et al. BRITISH JOURNAL OF CANCER
- Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies
- (2016) Yoichi Imai et al. CANCER SCIENCE
- Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research
- (2016) Gabriele Giacomo Schiattarella et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia
- (2016) Norbert Vey et al. LEUKEMIA & LYMPHOMA
- Targeting histone deacetylases in T-cell lymphoma
- (2016) Alison J. Moskowitz et al. LEUKEMIA & LYMPHOMA
- Pharmacogenomics and histone deacetylase inhibitors
- (2016) Andrew KL Goey et al. PHARMACOGENOMICS
- UGT genotyping in belinostat dosing
- (2016) Andrew K.L. Goey et al. PHARMACOLOGICAL RESEARCH
- Histone Deacetylase Inhibitors Prolong Cardiac Repolarization through Transcriptional Mechanisms
- (2016) Stan Spence et al. TOXICOLOGICAL SCIENCES
- Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
- (2016) Ivan Kopljar et al. Stem Cells Translational Medicine
- Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
- (2015) Y. Shi et al. ANNALS OF ONCOLOGY
- Targeting Histone Deacetylases in Diseases: Where Are We?
- (2015) Rosaria Benedetti et al. ANTIOXIDANTS & REDOX SIGNALING
- A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin
- (2015) Neeraj Agarwal et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I study of resminostat in Japanese patients with advanced solid tumors
- (2015) Satoru Kitazono et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
- (2015) A. M. Evens et al. CLINICAL CANCER RESEARCH
- Valproate in the treatment of epilepsy in girls and women of childbearing potential
- (2015) Torbjörn Tomson et al. EPILEPSIA
- First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies
- (2015) Kyu-pyo Kim et al. INVESTIGATIONAL NEW DRUGS
- Favorable results after conservative management of 316 valproate intoxicated patients
- (2015) Hossein Hassanian-Moghaddam et al. Journal of Research in Medical Sciences
- HDAC Inhibitors as Novel Anti-Cancer Therapeutics
- (2015) Cristabelle Souza et al. Recent Patents on Anti-Cancer Drug Discovery
- Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
- (2015) Philip T. Sager et al. Cancer Medicine
- A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function
- (2014) Sunil Sharma et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions
- (2014) Salvatore Gentile CNS SPECTRUMS
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
- (2014) Thomas Prebet et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
- (2013) A. T. Brunetto et al. CLINICAL CANCER RESEARCH
- A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors
- (2013) B. Venugopal et al. CLINICAL CANCER RESEARCH
- QTc prolongation and valproate toxicity
- (2013) Sara Kazim et al. CLINICAL TOXICOLOGY
- QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: A case report and review of the literature
- (2012) Donald R. Lynch Jr et al. Cardiology Journal
- Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed
- (2012) Berkley E Gryder et al. Future Medicinal Chemistry
- Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
- (2011) Paul Hamberg et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor
- (2011) Yanis Boumber et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors
- (2011) Michael D. Shultz et al. JOURNAL OF MEDICINAL CHEMISTRY
- Unknown
- (2011) Charles Dinarello et al. MOLECULAR MEDICINE
- Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer
- (2011) Nan-Soon Wong et al. Pharmacogenetics and Genomics
- Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin
- (2010) Akiko Hayashi et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular and Therapeutic Potential and Toxicity of Valproic Acid
- (2010) Sébastien Chateauvieux et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
- (2010) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone Deacetylase: A Potential Therapeutic Target for Fibrotic Disorders
- (2010) M. Pang et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
- (2009) Monica Galli et al. ANNALS OF HEMATOLOGY
- A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer
- (2009) P. N. Munster et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search